Dr. Chan on ExteNET Trial for HER2+ Breast Cancer

Dr. Jahanzeb on the APHINITY and ExteNET Trials in Breast CancerПодробнее

The ExteNET TrialПодробнее

The ExteNET TrialПодробнее

Ten News Professor Arlene Chan & Shereen Jolly on NeratinibПодробнее

Dr. Barcenas on Neratinib-Related Diarrhea in HER2+ Breast CancerПодробнее

Post-Adjuvant Therapy for HER2+ Breast CancerПодробнее

ExteNET and NEfERTT Clinical Studies in Metastatic Breast CancerПодробнее

The ExteNET Study & Management of HER2+ Breast CancerПодробнее

Understanding the ExteNET TrialПодробнее

Finding appropriate doses for HER2 positive breast cancersПодробнее

Dr. Pegram on Challenges in Neoadjuvant Treatment for HER2-Positive Breast CancerПодробнее

Dr. Hamilton Discusses the KATHERINE Trial in HER2+ Breast CancerПодробнее

Dr. Marks on the Role of TKIs in HER2-Positive Breast CancerПодробнее

Dr. Yee on Phase II ADAPT Trial Results for HER2+/HR+ Breast CancerПодробнее

Radiation Therapy Based on LUMINA Trial | Cynthia Ma, MD, PhD | ASCO22 Breast Cancer UpdatesПодробнее

Dr. Rimawi Discusses KATHERINE Trial in HER2+ Breast CancerПодробнее

Optimal Timing for NeratinibПодробнее

Pending FDA Approval of Neratinib in HER2+ Breast CancerПодробнее

Reviewing LORELEI, mindACT and ExteNET trials in breast cancerПодробнее